Cambium Bio Ltd. (CMB)
Market Open
ASX ASX Primary 13.12M Market Cap
- P/E Ratio
- Div Yield
217 Volume
- Eps
Want to track CMB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
CMB is not paying dividends to its shareholders.
The last earnings report, released on Feb 25, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Cambium Bio Ltd. has completed 1 stock splits, with the recent split occurring on Jul 04, 2024.
The company's stock is traded on one exchange.
Cambium Bio Ltd. (CMB) FAQ
On which exchange is it traded?
Cambium Bio Ltd. is listed on ASX.
What is its stock symbol?
The ticker symbol is CMB.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 13.12M.
Has Cambium Bio Ltd. ever had a stock split?
Cambium Bio Ltd. had 1 splits and the recent split was on Jul 04, 2024.
Cambium Bio Ltd. Profile
| Health Care Technology Industry | Healthcare Sector | Dr. Edmund Kemp Waller FACP, M.D., Ph.D. CEO | ASX Exchange | AU000000RGS6 ISIN |
| AU Country | - Employees | - Last Dividend | 4 Jul 2024 Last Split | - IPO Date |
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Contact Information
Address: Unit 2.06/31 Lexington Dr, Bella Vista, NSW, Australia, 2153
Phone: 61 13 0099 5098
Website: https://www.cambium.bio
